The Lieutenant Governor of New York, Kathleen Hochul, visited the Avery Biomedical headquarters March 2. Hochul came to tour the facilities and met with the entire Avery team.
She arrived warm and welcoming, greeting our Communications Coordinator, Nicole Ficarra, personally, calling her “the social media expert.” Our president Tony Martins then presented Hochul with the Avery medical devices, including the first pacers to the most current model.
Hochul then toured the grounds of Avery and learned about the manufacturing process. “Learning about the history of pacing @averybiomedical,” Hochul posted on Twitter after her visit.
The Avery Diaphragm Pacing System is an implanted phrenic nerve or diaphragm stimulator. It consists of surgically implanted electrodes and receivers with an external transmitter and antennas.
The Avery Diaphragm Pacing System is the only diaphragm pacing system to have full premarket approval (PMA) from the US FDA and CE Marking privileges under the European Active Implantable Medical Device Directive for adult and pediatric use. In addition, using small implanted radiofrequency receivers rather than electrode wires that pass directly through the skin may decrease a patient’s risk of infection and ongoing wound care management issues.
Avery has been commercially distributing diaphragm pacing systems since the early 1970’s. Since then, more than 2,000 patients have been implanted in over 40 countries establishing an unsurpassed record of safety and reliability. Due to their high reliability and cost effectiveness, the Avery pacers are reimbursed by Medicare and most private and government insurance around the world.